A multi-institutional, retrospective, translational study of the relationship between histological immune-related signatures and clinical benefit of paclitaxel + bevacizumab therapy in HER2-negative advanced breast cancer

A multi-institutional, retrospective, translational study of the relationship between histological immune-related signatures and clinical benefit of paclitaxel + bevacizumab therapy in HER2-negative advanced breast cancer - TRI-BE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041493

Enrollment

156

Registered

2020-09-01

Start date

2020-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-negative advanced breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HER2-ABC patients who underwent PB therapy as their first-/second- line chemotherapy between January 2011 to December 2016 at participating institutes (Shizuoka Cancer Center, Hiroshima City Hiroshima Citizens Hospital, and Fukuyama City Hospital)

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
1.Expression-status of immune-related signatures in primary site 2.Relationships between overall survival (OS)/time-to-treatment failure (TTF) and expression status of immune-related signatures in primary site	—

Secondary

Measure	Time frame
1.Relationships between overall survival (OS)/time-to-treatment failure (TTF) and expression-status of immune-related signatures in metastatic site 2.Relationships between peripheral immune-related markers/nutritional markers and expression-status of immune-related signatures in metastatic site 3.Changes in markers of epithelial-mesenchymal transition between primary site and metastatic site 4.Relationships between peripheral immune-related markers/nutritional markers and clinical efficacy	—

Measure

Time frame

1.Relationships between overall survival (OS)/time-to-treatment failure (TTF) and expression-status of immune-related signatures in metastatic site 2.Relationships between peripheral immune-related markers/nutritional markers and expression-status of immune-related signatures in metastatic site 3.Changes in markers of epithelial-mesenchymal transition between primary site and metastatic site 4.Relationships between peripheral immune-related markers/nutritional markers and clinical efficacy

—

Countries

Japan

Contacts

Public ContactJunichiro Watanabe

Shizuoka Cancer Center, Shizuoka Division of Breast Oncology

j.watanabe@scchr.jp055-989-5222

Outcome results